Tag Archives: disease

The Seven Major Markets for Alzheimer’s Disease is Expected to be Worth $ 7.8 billion by the Year 2010

(PRWEB) April 6, 2006

Research and Markets (http://www.researchandmarkets.com/reports/c35223) has announced the addition of the Jain PharmaBiotech report: Alzheimer Disease – New Drugs, Markets and Companies to their offering.

Profiles of 139 companies involved in developing diagnostics and therapeutics for Alzheimer’s disease are presented along with their collaborations. The bibliography contains over 500 publications that are cited in the report. The report is supplemented with 39 tables and 11 figures.

Alzheimer’s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

Early diagnosis of Alzheimer’s disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.

The current management of Alzheimer’s disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer’s disease is being recognized.

Research in Alzheimer’s disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 200 different compounds are at various stages of development for the treatment of Alzheimer’s disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Over 104 clinical trials are listed, of which 77 are still in progress and 27 were discontinued for various reasons.

Alzheimer’s disease market in the seven major markets is worth $ 6.1 billion in the year 2005 and will increase to $ 7.8 billion by the year 2010. The share of currently approved drugs specifically for AD is expected to be $ 3.1 billion in the year 2005 and $ 4.1 billion by the year 2010 provided all of them stay in the market. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2015. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

For more information visit http://www.researchandmarkets.com/reports/c35223

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###



Find More Early Onset Alzheimers Press Releases

Genetic Disease Foundation Encourages Americans to Know Their Genes at KnowYourGenes.org in Observance of World Rare Disease Day


New York, NY (PRWEB) February 28, 2010

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation(GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening ? an inconsistency that can have serious implications on a person?s overall health and the health of their immediate family members.

While it is public knowledge that disease risk can be reduced by living a healthy lifestyle, few are aware of the strong role that genetics and family history play in a person?s current and future health. In fact, almost every human trait and disease has a genetic component and there are more than 6,000 known genetic disorders, from widely recognized conditions like Down syndrome, spina bifida and sickle cell anemia, to lesser-known conditions like Tay-Sachs disease and Fabry disease. Approximately 10 percent of all adults and 30 percent of children in hospitals are admitted due to genetically-related problems.1

?Genetic disorders come in all shapes and sizes and are often undiagnosed or diagnosed too late due to lack of awareness around genetic testing and its benefits,? said Dr. Robert Desnick, Professor and Chairman of the Department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine and Medical Advisor to the Genetic Disease Foundation. ?While many genetic disorders are not fatal, some are, and many can significantly impact your quality of life. That is why it is so important that Americans take a more proactive role in getting to know and understand their genes, be it through education, genetic testing or by speaking with a genetic counselor.?

Genetic diseases are caused by abnormalities in a person?s DNA and can range from a small mutation in a single gene to the addition or subtraction of an entire chromosome or set of chromosomes. These abnormalities can disrupt the normal function of a vital system, such as the immune system or the nervous system, or prevent normal development of organs, bones or skin, significantly increasing a person?s chance of developing a particular disease.

It?s In Your Genes: Genetic Testing and Your Health

Genetic testing can reveal whether a person carries gene mutations associated with certain inherited diseases. The test involves analyzing blood, tissue or saliva for evidence of genetic abnormalities. Genetic tests typically fall into three categories: carrier screening to determine whether adults carry a gene mutation that could cause disease in their children, prenatal diagnostic to learn if a fetus is affected and predictive testing to discover the presence of gene mutations that may put a person at a higher risk for a particular disease, such as cancer or diabetes.

The purpose of genetic testing is to allow for early detection, which in turn can lead to early intervention to prevent the onset of symptoms or minimize disease severity. Genetic testing has helped thousands of individuals and families prevent or prepare for hereditary diseases and make informed decisions about their healthcare. However, because of the physical and emotional implications associated with a genetic disease diagnosis, many people prefer not to know that they may be at risk. The Genetic Disease Foundation found that 63 percent of those surveyed did not know if they or someone in their family had a genetic disorder. In addition, the survey revealed that preferring to not know about their risk for a genetic condition ranked among the top three reasons for not undergoing genetic testing.

?Determining your personal risk for genetic disorders, or that of your child, is one of the best and most responsible ways of managing your family?s health,? said Dr. Desnick. ?For that reason, it is essential that we educate ourselves about the long-term benefits of knowing your genetic makeup, and KnowYourGenes.org is a valuable and free resource from the Genetic Disease Foundation to help us do so.?

KnowYourGenes.org: A New Easy-to-Understand Resource on Genes and Genetic Testing

In observance of World Rare Disease Day on February 28, 2010, the Genetic Disease Foundation is launching KnowYourGenes.org ? a new easy-to-understand resource for people who are planning a family, have a family member or friend with a genetic disease or have a personal interest in undergoing genetic testing.

?KnowYourGenes.org was created to address the lack of easy-to-understand information out there about genetic testing and the role genes play in your health,? said Elisa Ross, President of the Genetic Disease Foundation. ?GDF is proud to bring this resource to all those who want to take a preventive and proactive approach to their health and the health of their family.?

In addition to providing helpful information on genetic diseases and testing, KnowYourGenes.org also includes a quiz to determine who should undergo genetic testing and where to find the nearest genetic testing location and personal genetic counselor.

For more information, visit http://www.KnowYourGenes.org.

About The Genetic Disease Foundation

The Genetic Disease Foundation (GDF) is a 501(c)(3) not-for-profit organization established in 1997 by patients and families affected by genetic disorders. The Foundation?s mission is to support research, education and the prevention of genetic diseases. The GDF supports: education programs to increase awareness about genetic diseases and the need for and availability of genetic testing; research to improve genetic testing and discover ways to treat, cure and ultimately prevent genetic disorders; and genetic counselors and health professionals with experience in medical genetics and counseling. The Genetic Disease Foundation is affiliated with the Mount Sinai School of Medicine’s Department of Genetics and Genomic Sciences, whose faculty lead the country in clinical research to improve prenatal diagnosis, carrier screening, genetic counseling methods, and therapies for genetic diseases.

For more information on the Genetic Disease Foundation, visit http://www.GeneticDiseaseFoundation.org.

Reference:

1. Nussbaum, RL, McInnes RR, Willard HF. Thompson & Thompson’s Genetics in Medicine, 7th ed. 2007, WB Saunders Company, Philadelphia, PA

For additional information, please contact:

Fleishman-Hillard

Mariana Rodrigues

+ 1 212.453.2351

###







Free Alzheimer?s Disease Test in Honor of National Alzheimer?s Disease Month

Georgetown, TX (PRWEB) September 6, 2006

November is National Alzheimer’s Disease Month, so ALZ-HELP.org has developed a free on-line test, taken in the privacy of your own home, which has been specifically created with questions designed to indicate your risk factors and possible early warning signs of Alzheimer?s disease. This tool was created to help you and your health care provider become more aware of early symptoms that could indicate future problems.

Medical research statistics indicate that the older we get, the higher the odds become of getting Alzheimer?s disease. Alzheimer?s disease is the most common cause of dementia in older adults and this progressive deteriorating brain disorder results in gradual memory loss, personality changes, unusual behavior, and a decline in thinking abilities. It currently affects over 4-5 million Americans and many millions more worldwide. The current baby boomer generation is quickly approaching the age of greater risk for Alzheimer?s and as many younger people reach their 50?s and 60?s, they may develop early onset Alzheimer?s.

This simple test is completely private and is not recorded by Alz-Help or anyone else. Share the results with your health care specialist. For best results, retake this free test every few months and compare your progressive scores.

Although a cure for Alzheimer?s has not yet been developed, active mental exercises, like crossword puzzles, Sudoku and other activities, as well as a healthy diet, have been known to help delay its onset.

For your free online test, visit http://www.alz-help.org.

###







Bel Marra Health Comments on a Recent Study that Shows Women with Heart Disease are More Likely to have Baby Girls


Toronto, ON (PRWEB) May 05, 2012

Bel Marra Health, well known for offering high-quality, specially formulated vitamins and nutritional supplements, has commented on a recent study that shows the connection between women with heart disease and the likelihood of having a baby girl.

Researchers at the World Congress of Cardiology reviewed the gender of 216 babies who were born to women who had been diagnosed with a cardiovascular disorder such as heart disease. They found that 75% of the babies born to these women were female. Amongst these women, 64% were suffering with valvular disease, 19% with dilated cardiomyopathy and 14% with uncorrected or significant residual congenital heart disease.

Dr. A. Alizadehasl, from Tabriz University, Tabriz, Iran, reports ?We believe that this is the first study looking at the relationship between gender and the mother?s cardiac disease.?

?This is a very interesting observation. The chromosomes in a man?s sperm are responsible for the sex of a baby but this study does suggest that there may be a relationship between the health status of the mother and the sex of the babies that she is able to carry to full-term,? adds Dr. Kathryn Taubert, Chief Science Officer, World Heart Federation.

Spokesperson for Bel Marra Health, Dr. Victor Marchione says, ?although many women may desire a baby girl, it is probably safe to say that none of them would sacrifice their good health in order to increase their odds of having one. Proper cardiac care and good health are vitally important for a healthy pregnancy and the delivery of a healthy baby.?

In addition to exercising and eating a whole food based diet, you can reduce your risk for cardiac disease by quitting smoking, reducing alcohol intake and maintaining a healthy weight. Finally, you can magnify the effects of this cardiac care lifestyle by emphasizing the following heart-supporting super foods ? berries, cold-water fish, oatmeal, spinach and olive oil.

(SOURCE: ?World Heart Federation.?Women with heart disease more likely to have baby girls, April 2012)

Bel Marra Health, the maker of Heart Rescue, a formulation built in optimal dosages to help maintain heart health, offers quality vitamins and nutritional supplements in formulations designed to address specific health concerns. All ingredients are backed with scientific evidence. Every product is tested for safety, quality, and purity at every stage of the manufacturing process. Furthermore, Bel Marra Health products are produced only in Health Canada approved facilities, going that extra mile to ensure our health conscious customers are getting top quality products. For more information on Bel Marra Health visit http://www.belmarrahealth.com or call 1-866-531-0466.

Bel Marra Health

100-7000 Pine Valley

Woodbridge, ON L4L 4Y8

pr(at)belmarrahealth(dot)com

866-531-0466

http://www.belmarrahealth.com







Related Cardiovascular Disease Press Releases

May Marks Lyme Disease Awareness Month: Is Lyme Disease The Next Tsunami Fact or Fiction?


San Diego, CA (PRWEB) May 2, 2007

In honor of May 2007 Lyme Disease awareness month, Christine N. Cibula, M.S., founder of Living with Lyme? (http://www.LivingWithLyme.com and http://www.LivingWithLymeBlog.com), a Division of Strategic Living, Inc. (http://www.Strategic-Living.com), shares little known facts while demystifying the fiction surrounding Lyme Disease.

Christine Cibula said, “There are millions of people worldwide who are ‘Living With Lyme’ and don’t know it because they have been misdiagnosed with another disease or they are silently suffering after they’ve heard their physicians say, ‘Lyme disease does not exist in (City, State).’ This is simply not true. I’ve opted to shed light on this topic by sharing medically and scientifically documented fact in the hopes that the facts will replace the fiction in the medical community and that Lyme patients will begin to receive the appropriate diagnosis, treatment, and follow-up care as the norm rather than the exception.”

FACT: It takes one to three days for the Lyme spirochete, a worm-shaped bacteria known as Borrelia burgdorferi (Bb), to migrate from the site of the tick bite to the heart, joints, and central and peripheral nervous system.

FACT: A microscopically small bacterial load of 500 Bb can populate an entire human host.

FACT: Animals that can harbor active Lyme disease infections include the well-known deer and mice, but the list includes wild animals such as elk, migrating birds, rabbits, rats and domestic animals such as horses and dogs. Wild animals migrate and some travel long distances. Domestic animals travel and some are shipped to and from locations, such as domestic pets or animals that travel for competitions. Therefore, even if the area where you live is not considered “endemic” for Lyme disease, exposure is still possible or you may have momentarily traveled to an “endemic” area and been exposed without realizing it.????

FACT: While ticks are the primary vectors for the transmission of Lyme disease, Bb has been found in the blood of horse flies, fleas, chiggers, mites, etc. Some patients who present with symptoms of Lyme disease report never having been bitten by a tick, but do remember the onset of symptoms after being bitten by another vector that has been found to carry the bacteria in its blood.

FACT: Ticks carry on average 13 different bacteria, viruses, and mycoplasma. Patients with Persistent Chronic Lyme disease are often co-infected with other bacteria, viruses, and mycoplasma that have gone untreated if a physician has only treated the Lyme disease itself. These include but are not limited to Babesia, Bartonella, Erlichia, H. pylori, Mycoplasma, Tularemia, HIV, HPV, Q Fever, Rocky Mountain Spotted Fever. Morgellon’s patients are typically co-infected with Lyme disease and improve significantly with antibiotic therapy.

FACT: The testing for Lyme disease is two-tiered, starting with an ELISA. For every 100 true positive patients who have Lyme disease, 51-67 patients presenting with early stage Lyme disease are told that they do not have it and 21 patients presenting with late stage Lyme disease are told that they do not have it based on ELISA tests that are not sensitive enough for accurate detection.

FACT: The current Lyme Western Blot used by most laboratories across the country was developed using samples of patients who had Lyme disease for 5 months or less which does not include samples from patients with mid or late stage Lyme disease, is not capable of detecting STARI, also known as Master’s Disease, and are analyzed by “autonomic densitometers” (i.e., machines rather than human technicians). As a result 33 out of 100 true positive Lyme patients will be told based on poor Lyme Western Blot testing measures that they do not have Lyme disease when in fact they do. These patients go on to often be misdiagnosed with Multiple Sclerosis, Fibromyalgia, Chronic Fatigue, Lupus, Myesthenia Gravis, Bell’s Palsy, Paralysis, ALS, Delusions, Schizophrenia, Bipolar Disorder, Dementia and Alzheimer’s. Borrelia burgdorferi has been found to mimic each of these diseases as well as many more and therefore should be ruled out as a differential diagnosis.

FACT: Lyme disease is a spirochete much like syphilis. It has been found in every organ and every bodily fluid in the body. It has been found to pass from mother to fetus as Gestational Lyme. In babies born with Lyme disease, 75% show Neuropsychiatric Symptoms including Autism (9%) and Attention Deficit Hyperactivity Disorder (56%) and 63% have Neurological Sensory Integration Problems and Hypersensitivities. Just like with syphilis, people with Bb in the body may be asymptomatic for Lyme disease for years and in some cases longer than a decade before they show signs and symptoms of late stage disseminated Lyme disease. During this time they could be unknowingly passing the disease between sexual partners and from mother to fetus.

FACT: Borrelia burgdorferi has several forms – spirochete, cyst, blebs, intracellular and extracellular, with cell walls and without cell walls, and can morph and splice its DNA and combine with the DNA of the human or animal host and hides from the human immune system. It takes a host of combination antibiotic therapy protocols to effectively treat all its forms. International Lyme and Associated Diseases Lyme Literate Medical Doctors (ILADS LLMDs) are well-versed in these treatment protocols.

FACT: Borrelia burgdorferi migrates to joint and synovial fluids, cardiac tissue, reproductive tissue, and the brain, spinal cord, and nerve fibers, which directly affects the central and peripheral nervous system. In short, it damages every organ system of the body.

FICTION: Lyme disease does not exist in (City, State).

FICTION: Lyme disease is being over diagnosed and over treated.

FICTION: Lyme disease patients are attention seeking excuse makers.

FICTION: Lyme disease is cured by a 10-day dose of Doxicycline.

FICTION: Persistent Chronic Lyme cannot be treated with antibiotic therapy.

FICTION: The Infectious Diseases Society of America (IDSA) Treatment Guidelines are sufficient and curative.

FICTION: Lyme disease can’t kill you.

Is Lyme disease the next tsunami fact or fiction? You be the judge. Living with Lyme will be providing more free educational information about Lyme disease awareness throughout May 2007. To learn more about how to safeguard and protect your family visit http://www.livingwithlyme.com/lyme_awareness_may_2007.html. Living With Lyme will be providing patient education on symptoms and differential diagnosis, the one laboratory in the country that has highly sensitive and specific testing, and how to find an ILADS LLMD to oversee your ongoing treatment and care.

About Living With Lyme: Christine N. Cibula, M.S. founded Living With Lyme (http://www.LivingWithLyme.com and http://www.LivingWithLymeBlog.com) in 1999 after being diagnosed wtih Lyme disease and realizing she had been suffereing with Lyme for 11 years prior to being accurately diagnosed. Her symptoms resolved after year of high dose antibiotic therapy. As she read the research she discovered that the basic information most people know about Lyme disease is just the tip of the iceberg. In response she created Living With Lyme to get Lyme patients up to speed quickly with everything they need to know and nothing they don’t. To sign up for her Free Living With Lyme Ezine and enjoy a Free Teleseminar Lyme Educational Series in May 2007, visit http://www.LivingWithLyme.com/lyme_awareness_may_2007.html and sign up today!

###







New Book Described as Powerful, Revealing, Provides a Unique Insight into Chronic Mental Disease According to Dr. Thomas Burish af The University of Notre Dame


(PRWEB) November 09, 2011

What A Life Can Be: One Therapist’s Take on Schizo-Affective Disorder, Dr. Burish described as “a probing, honest, liberating story.” Dr. Burish is both a professor of psychology and the Provost of Notre Dame in South Bend, Indiana.

George E. Doebler, M Div., the special advisor in the Dept. of Pastoral Care at the University of Tennessee Medical Center and the Executive Director, emeritus: Association of Mental Health Clergy? (now Association of Professional Chaplains) said this: ?is a book for those who are not faint hearted, who want to be challenged while they are entertained. It will challenge your thinking about mental illness, about hope, about faith, about who you are”.

He went on to say this “is a story about our difficulty with those we label as mentally ill. It is about how health care does not know what to do with those who are mentally ill….it is easier to simply say they are crazy, give them a pill (which can be very helpful if wisely prescribed) and send them to the street.”

Dr. Carolyn Dobbins’ patient, Jane, was on track to become a member of the US Winter Olympics Ski team in Lake Placed. She didn’t make it! She was felled with what turned out to be a severe mental illness that caused her to drop out of athletics. Over the next two decades, she struggled to complete her university education despite periods of homelessness and even jail.

At one point in her university career, Jane went from a jail cell where she was being held without having been charged to a psychiatric hospital and then, within weeks, she managed to successfully defend her doctoral thesis. During her struggles, Jane was also a successful singer/performer in Branson, MO.

As Rev. Doebler added, “The dialogue between the therapist and the patient is philosophical, witty, sad, frightening, caring –and lovingly done.”

The story will fascinate readers who will be surprised by its dramatic ending. Dr. E Fuller Torrey, the highly acclaimed author of Surviving Schizophrenia and Executive Director of The Stanley Medical Research Institute in Chevy Chase, MD called the book ?an inspiration?. The National Alliance on Mental Illness , in an advance review, wrote that ?this book shows how people are more than their illness, their profession or their position in a family.?

In the Afterword, Dr. Kenneth O Jobson, a Knoxville psychiatrist and psychopharmacologist said ?this book gives a model of resilience and success in dealing with a troubling and potentially lifelong disabling psychiatric illness – a model that conveys a strategy of action and attitude.?

Dr. Dobbins lives and works in Knoxville. She received her BS from the University of Utah and her PhD from Vanderbilt University in 1990. She is the recipient of a National Institute of Mental Health scholarship, two clinical fellowships along with four research assistanship’s and a research associateship. She is a member of the American Mental Health Counselors Association and is licensed in Tennessee and Missouri.

What A Life Can Be: One Therapist’s Take on Schizo-Affective Disorder is published by Bridgeross Communications and distributed by Ingram Books. It is available at Amazon, Barnes and Noble and other book retailers. ISBN 978-0-9866522-2-2-6, 225 pages, $ 19.95.

The book includes Facts About Mental Illness, Dr Dobbins 6 A’s of Self Help,and a note to her counseling colleagues.

Dr. Dobbins is interested in speaking opportunities and media interviews. She can be contacted through her publisher.

###







Report Describes 300 Compounds in Development for Treatment of Alzheimer’s Disease

(PRWEB) October 26, 2007

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which forecasts the market-share for various approaches in the treatment of Alzheimer’s disease to 2016

“Alzheimer’s Disease: New Drugs, Markets and Companies” reports that considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors, beta amyloid deposits and neurofibrillary tangles. Acetylcholinesterase inhibitors do not correct the basic pathology of the disease. Also, several new approaches emphasise neuroprotection.

The study shows that acetylcholinesterase inhibitors are mostly a symptomatic treatment; however, some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behaviour and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer’s disease is being recognized.

There are nearly 8 million sufferers from Alzheimer’s disease in the seven major markets of the world, and this is anticipated to increase in the future.

Research in Alzheimer’s disease still aims at elucidating the basic pathomechanisms. This can be made by animal models, which are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer’s disease which are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials.

“Alzheimer’s Disease: New Drugs, Markets and Companies” shows that there are several new therapies expected to be in the market, and the shares of various types of approaches are estimated for the future up to the year 2016. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

“Alzheimer’s Disease: New Drugs, Markets and Companies” is available in pdf format from Piribo. For more information go to: http://www.piribo.com/publications/diseases_conditions/alzheimers/alzheimers_disease.html

Piribo product ID: JAI002

About Piribo.

Piribo (http:http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

# # #







Related Early Onset Alzheimers Press Releases

Alzheimer’s Foundation of America Symposium: Identifying Young-Onset Alzheimer’s Disease


New York, NY (Vocus) April 10, 2008

They are too young to forget the faces of loved ones. They are too young for missed appointments and shattered memories. They are too young for Alzheimer’s disease. But maybe not. While Alzheimer’s has long been associated with old age, new evidence is mounting that the disease can and does appear in mid-life, though it is rare.

On Friday, April 11th, the Alzheimer’s Foundation of America is hosting a symposium for patients, caregivers and health professionals to talk about the growing number of people under 65 diagnosed with Alzheimer’s disease. Contrary to popular belief, the majority of middle-aged patients do not have an obvious family history, according to Peter Davies, Ph.D., scientific director of the Litwin-Zucker Research Center for the Study of Alzheimer’s Disease and Memory Disorders at The Feinstein Institute for Medical Research, based in Manhasset, NY. Dr. Davies, a world leader in Alzheimer’s, will talk about the young patients he has seen over his 30-year research career and how they have shaped his opinions about the mind-robbing disease.

Dr. Davies started his investigations into Alzheimer’s disease in the 1970s. He was a scientist at the Albert Einstein College of Medicine in the Bronx and doctors began sending him brains from all over the country. Over the decades, 6,000 autopsied brain samples have passed through his microscope. Dr. Davies and his colleagues found that about 80 percent of those autopsy samples showed the classic pathological Alzheimer’s plaques and tangles. Of those 6,000 patients, only 58 of them were under 65. The average age of onset was about 53.

By the 1990s, several early onset genes were identified in a handful of families with dozens, even hundreds, of affected family members. Scientists studying these so-called early onset families have now found more than 100 mutations in the presenilin genes, PS1 and PS2. There are also families that have a rare mutation in a gene called amyloid precursor protein. Dr. Davies studied the DNA from the younger patients in an attempt to identify genetic causes. Surprisingly only four of the 58 patients had the genetic mutations known to cause Alzheimer’s.

Of those four patients, two of them were brothers with a PS1mutation and two were an uncle and niece with a PS2 mutation. No one in the group had an APP mutation.

That did not surprise Dr. Davies, who understood that these mutations are extremely rare in the population. And Alzheimer’s is very common, with one in four people between the ages of 80 and 85 suffering from the brain disease. Dr. Davies says that the rates of Alzheimer’s can be laid over a bell curve, with the mean age of patients diagnosed between 80 and 85 and then heading downward in both directions in younger and older ages. If that’s the case, the risk for Alzheimer’s is diminished in old age and doctors are less likely to diagnose Alzheimer’s in people over age 90. But that also means that there are going to be people diagnosed on the left side of the bell curve when they are in their 40s, 50s or 60s. He suspects that there are probably a dozen or so genes that put people of all ages at risk for Alzheimer’s and very few of these genes are known.

“There’s a vulnerable brain,” said Dr. Davies. “But there is also something else, either stress, head injuries, environmental effects. We just don’t know. But these effects interact with the genes to trigger Alzheimer’s disease.”

Scientists working in the Davies lab at the Feinstein Institute are identifying new risk genes for Alzheimer’s. A risk gene is different from the PS1, PS2 and APP mutations in patients with a family history of early-onset disease. These inherited mutations, while rare, cause the disease. Risk genes, by contrast, tip the scales in the direction of disease, but having a risk gene does not mean a person will develop Alzheimer’s.

Dr. Davies will also talk about the treatments for Alzheimer’s, which help to slightly improve cognition but don’t stop the course of the disease process. The disease course generally runs about a decade from the time of diagnosis to death. It is the hope that research being conducted today will lead to medicines that truly work to stop Alzheimer’s in its tracks in the next decade.

“Preparing for the Crisis: Diagnosing & Caring for People in Their 30′s, 40′s & 50′s with Young Onset Alzheimer’s Disease” is being sponsored by the Alzheimer’s Foundation of America (AFA) and the Sid Jacobson JCC, which is located in East Hills, Long Island. The symposium will be held at The Lighthouse Executive Conference Center located at 111 East 59th St. in Manhattan from 8 am to 1 pm. The Sid Jacobson Center has an innovative program for young people diagnosed with Alzheimer’s. Some of the clients and their families will be speaking at the meeting, as well. To register for the symposium call 866-232-8484.

For more information on the Feinstein Institute, visit http://www.feinsteininstitute.typepad.com.

Contact:

Jamie Talan

Science writer-in-residence

516-562-1232 / 631-682-8781

# # #







Find More Early Onset Alzheimers Press Releases

Jacksonville Periodontist Introduces New Laser Gum Disease Treatment For Moderate to Severe Periodontal Disease


Jacksonville, FL (PRWEB) May 09, 2012

Dr. Walter Wood, a periodontist in Jacksonville, FL, has introduced the LANAP (Laser Assisted New Attachment Procedure) Laser Therapy for the treatment of moderate to severe periodontal disease. With many recent studies finding a connection between gum disease and an increased risk for heart disease, pancreatic cancer, stroke, and low-birth-weight babies, seeking treatment of diagnosed periodontal disease has never been more important. However, many patients continue to avoid treatment because it is traditionally performed using scalpels and sutures.

Traditional periodontal surgery involves the cutting of the gums in order to access the affected teeth. The tooth root is then cleaned, the diseased gum tissue is trimmed away, and the gum line is often lowered. A lower gum line can often result in aesthetic issues as well as an increased sensitivity to hot or cold. Following surgery, some patients report moderate to severe pain and may require one or more days off of work in order to recover.

The LANAP Laser Therapy treats periodontal disease but without the use of scalpels or sutures as with traditional surgery. Instead, the LANAP Laser Therapy works by operating at a wavelength of light that can differentiate between diseased tissue and healthy tissue. The laser essentially eliminates the bacteria from the mouth that cause gum disease, removing the disease without harming the healthy tissue. The LANAP Laser Therapy does not use scalpels. Because the gums are not cut, there is very little, if any, gum recession. The LANAP Laser Therapy is the first and only FDA cleared laser treatment for periodontal disease and has allowed Dr. Wood to see fantastic, predictable long-term results.

Dr. Walter Wood, a leading periodontist in Jacksonville, believes strongly in providing his patients with the latest in state-of-the-art treatment options. He has received extensive training in dental implants, periodontal plastic surgery, and LANAP. His office is located at 711 Baymeadows Road East, Suite 7 in Jacksonville, Florida 32256. More information about LANAP can be found by calling 904-416-1436, or visiting http://www.jacksonville-periodontist.com.







Related Cancer Press Releases

QuickMedical Announces Study Linking High Cholesterol Levels to Increased Risk for Developing Alzheimer’s Disease or Vascular Dementia


Issaquah, Wa (PRWEB) May 01, 2012

QuickMedical, a leading distributor of the CardioChek? cholesterol testing instrument for healthcare professionals, and the CardioChek? home cholesterol analyzer released a statement today hailing a new study by Kaiser Permanente. The study suggests that high cholesterol levels are a significant risk factor for developing dementia and Alzheimer’s Disease later in life.

The results of the study were published in the journal of Dementia & Geriatric Cognitive Disorders. The research study tracked 9,844 men and women for four decades, starting when the participants were between 40 and 45 years of age.

After controlling for weight, hypertension and diabetes, the researchers discovered a significant link between borderline-high cholesterol and dementia.

The participants in the study, who had high cholesterol, or a value of 240mg/dl or more, had a 66 percent greater risk of developing Alzheimer’s Disease later in life. People with borderline-high cholesterol, between 200 and 239, had a 25 percent spike in risk.

According to the American Heart Association, more than 106 million Americans reportedly have borderline-high cholesterol levels.

“With the availability of our CardioChek? cholesterol testing device for the healthcare professional and the CardioChek? analyzer for home use there is now a way for the public to know their cholesterol level number,” said Robert Huffstodt, President and CEO of Polymer Technology Systems. “The continued emergence of research findings such as these strongly reinforces the rationale for including cholesterol screenings as an integral part of healthcare preventative maintenance; not only with regards to heart disease and diabetes, but now with the risk of dementia and Alzheimer’s Disease.

The study concluded that people as young as 40 with borderline or high cholesterol levels are at increased risk for developing Alzheimer’s disease or vascular dementia. Previous studies have linked heart and brain health, but this study is the first to examine the association between borderline cholesterol levels and dementia.

About QuickMedical:

With a best price guarantee and over 31,000 items to choose from including professional medical equipment, disposable medical supplies, fitness and therapy products, along with a full line of home healthcare products, QuickMedical is your online medical supply store. Click here to see our current promotions.







Related Alzheimers Press Releases

Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv